Stryker Stock News

Stryker (SYK) delivered earnings and revenue surprises of -0.37% and 1.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Stryker (NYSE:SYK) is scheduled to announce Q4 earnings results on Thursday, January 27th, after market close.The consensus EPS Estimate is $2.72 (-3.2% Y/Y) and the consensus…

Stryker (SYK) through its wholly owned subsidiary, Voice Merger Sub commenced a cash tender offer to purchase all outstanding shares of common stock of Vocera Communications

Kalamazoo, Michigan, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) today announced that it is commencing, through a wholly owned subsidiary, Voice Merger Sub Corp., a cash tender offer to pur

Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Pune, India, Jan. 24, 2022 (GLOBE NEWSWIRE) -- The global medical devices market size is expected to reach USD 657.98 billion by 2028, exhibiting a CAGR of 5.4% during the forecast period. The rising geriatric population will boost the growth of the market. Fortune Business Insights, in a new study, titled "Medical Devices Market Size, 2021-2028." states that in-vitro diagnostics is expected to lead the market. According to the study, the US IVD segment covered 15.5% of the global medical devices market share in 2020. Key Development : January 2021: Stryker announced that it had acquired OrthoSensor Inc., a leader in the digital evolution of musculoskeletal care and sensor technology for total joint replacement, in order to include its Verasense intraoperative sensor technology in its portfolio of Mako robots. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/medical-devices-market-100085 Driving Factor : Rising Prevalence of Chronic Disorders and Demand for Preventive Healthcare to Spur Growth The rising incidence of chronic diseases such as diabetes, cancer, heart diseases is fueling the demand for various medical devices in North America.

Up to ~30% of Stryker's customers have elective issues; however, the underlying diseases are progressive so they delay rather than stop acquiring Stryker's products. COVID notwithstanding, Stryker rem

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

It's not too late to get in on these market-beating companies.

The surgical robotics leader produces tremendous results, but the pandemic has been a persistent headwind over the past two years.

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

It could be enough to cover the down payment on your dream beach house.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China''s National Medical Products Administration ("NMPA") has granted Breakthrough Therapy Designation ("BTD") to HMPL-523, a novel, investigational spleen tyrosine kinase ("Syk") inhibitor, for the treatment of chronic adult primary immune thrombocytopenia ("ITP") patients who have received at least one prior therapy. NMPA grants BTD to new drugs that treat life-threatening diseases or serious conditions for which there are no effective treatment options, and where clinical evidence demonstrates significant advantages over existing therapies. Drug candidates with BTD may be considered for conditional approval and priority review when submitting a New Drug Application (NDA). Christian Hogg, Chief Executive Officer of HUTCHMED, said, "ITP is an autoimmune bleeding disorder that can often be serious and can have a significant, multifaceted impact on patients'' health and quality of life.